THEME: "Exploring the Challenges in Pre & Post Formulations and Drug Delivery Systems"
Dubai Pharmacy College for Girls, Dubai, UAE
Title: Effect of Different Carriers on In vitro and In vivo Drug Release Behavior of Aceclofenac Proniosomes
Rana M.F Sammour has completed her MPharm and PhD in Pharmaceutical Technology. She is working as an assistant professor in Dubai Pharmacy College in the Pharmaceutics department. She has published many researches in international conferences and journals. The interest of her researches is mainly in drug development and novel drug delivery systems. The aim of her studies is to explore the role of the novel delivery systems in improving the pharmacokinetics parameters of drugs.
Improved
bioavailability of Aceclofenac may be achieved through proniosomes, which is
considered as one of the most effective drug delivery systems and is expected
to represent a valuable approach for the development of a better oral dosage
form as compared to the existing product. However, the carrier in this system
plays a vital role to control the drug release and modulate drug dissolution.
Accordingly, a comparative study between different carriers can give clear
ideas on the selection of carriers to prepare Aceclofenac proniosomes.
This
study aims to evaluate the role of maltodextrin, glucose, and mannitol as
carriers on in vitro and in vivo performance of Aceclofenac proniosomes.
Three
formulations of proniosomes were prepared by the slurry method using different
carriers, i.e., Glucose (FN1), Maltodextrin (FN2), and Mannitol (FN3). In
vitro, drug release studies were conducted by the USP paddle method, while in
vivo studies were performed in albino rats. Pure Aceclofenac was used as a
reference in all the tests. Lastly, the results were analyzed using the
High-Pressure Liquid Chromatography (HPLC) method, and data were evaluated
using further kinetic and statistical tools.
In in vitro drug release studies, the dissolved drug was found to be 42% for the pure drug, while 70%, 17% 30% for FN1, FN2, and FN3 respectively at 15 min. After 24 hrs, the pure drug showed a maximum of 50 % release while 94%, 80%, 79% drug release were observed after 24 hr for FN1, FN2, and FN3, respectively. The in vivo study conducted using albino rats showed a higher Cmax and AUC of FN1 and FN2 in comparison with the pure ACE. Moreover, the relative oral bioavailability of proniosomes with maltodextrin and glucose as carriers compared to the pure drug was 183% and 112% respectively. Mannitol based formulation exhibited low bioavailability (53.7%) may be attributed to its osmotic behavior.
These
findings confirm that a carrier plays a significant role in determining in
vitro and in vivo performance of proniosomes and careful selection of carrier
is an important aspect of proniosomes optimization